A Biosimilar Must Say It's A Biosimilar: PhRMA/BIO
This article was originally published in Scrip
To ensure prescribers and patients are informed a product is a biosimilar and not a brand-name biologic, and to protect against any inadvertent substitution of the two, the labeling for the copycat medicines should clearly state they are indeed, biosimilars, the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO) said in a new petition to the FDA.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.